Member Info for fatprofits

I would question that.

Why has Youngs' profitability returned to pre covid
levels approx, while FSTA appear to be under 50% of
their 2018 earnings.

Also their is family control of Fullers through ownership
of a different class of shares that are unlisted.

Anyone holding should understand the ownership/share
structure. The company sec may be able to help with this
if you want a detailed answer.

Mentioned this previously and it's beginning to look
more like we may be.

Load factor back to 96% and over 18 million passengers in one month,
fair does.

And how is that money repatriated form a Russian territory exactly?,
given the war. I thought there was a ban on money leaving Russia?.

about the future of the office ?.

Will offices largely become stranded assets?.

before the close

in that zone now at the close and I have started to add.

Possibly sub 60 pence a possibility, but if the latest acquisitions pay off
this arguably looks highly attractive - all IMV only as always.

Between 61-63.5 pence ? ..

I should stress the above is a guess Only.

I could not even guess at that.

There are potential litigation risks around medications,
GSK paid out $bn's in the US market on Advair -
but generated many more billions in pre tax profit
from Advair. From memory that was a
question of how the drug was marketed/sold -
rather than the compound itself.

Zantac was the medication that helped propel
GSK (Glaxo then) in to the big league.

It will not just be confined to the US market.

If this involves the prescription Zantac then we are looking
at the best selling drug globally by the late 1980's.

I was prescribed Zantac prior to the advent of proton pump inhibitors.

Like 99.99% of people I have little idea of how this ends.

an attempt at a subtle p1sstake?.

When you read posts such as..what is going on here..

Perhaps spend 60 seconds reading about last week's events.

To be fair that may leave you little the wiser
as possible litigation unknowns abound.

how do you even begin to quantify this.

And that is being kind.

Glaxo received FDA approval to sell Zantac in the US market in 1983,
by 1988 it was the world's best selling drug.

It was off patent in the US by 1997.

With respect, read the document
Https://www.gsk.com/media/8976/haleon-prospectus.pdf

"...2.4 Litigation, disputes and regulatory investigations may materially and adversely affect
the Group’s business, financial condition, results of operations and prospects
The Group is, and may in the future be, subject to legal proceedings, disputes and regulatory
and governmental investigations in various contexts, including consumer fraud actions,
competitor and regulatory challenges to product and marketing claims, competition law
investigations, product liability and quality claims, human resources claims, contractual
disputes and other disputes or claims arising in the ordinary course of its business operations.
These legal actions, disputes and investigations may relate to aspects of the Group’s
businesses and operations that are specific to the Group, or that are common to companies
that operate in the Group’s markets, and this risk may be enhanced in circumstances where
the Group is operating in new markets. Legal actions and disputes may arise under contracts,
regulations or from a course of conduct taken by the Group, and may be class actions.
For example, in the USA, the Group is a defendant in ongoing proton pump inhibitor (“PPI”)
litigation, in which plaintiffs have alleged that their use of PPIs caused serious bodily injuries.
The Group has filed motions to dismiss several hundred cases, but the court has not yet ruled
on those motions. In addition, certain members of the GSK Group and the Pfizer Group are
party to proceedings relating to the detection of N-Nitroso-dimethylamine in Zantac (ranitidine)
products. Pursuant to the Pfizer SAPA, the Group has certain indemnification obligations to the
GSK Group and the Pfizer Group in respect of “Purchaser Liabilities” and “Assumed Liabilities”
(each as defined in the Pfizer SAPA), which may include liabilities related to OTC Zantac (see
paragraph 3.5 of Risk Factors below). Further, in 2013, GlaxoSmithKline Consumer Healthcare
GmbH & Co. KG and other members of a German trade mark association were fined by the
Federal Cartel Office of Germany, as a result of the exchange of certain information during
meetings from 2004 to 2006. Following the fine, the Group has become party to several civil
proceedings in Germany for follow-on damages. An adverse outcome in such proceedings (or
any other related proceedings) may have a material adverse effect on the Group’s business,
reputation, results of operations and financial condition.
Although the Group has developed and implemented a set of standards, controls, and policies
and procedures that are highly tailored to the specific requirements of the Group and the
regulatory regimes of the jurisdictions in which it operates, there is no guarantee that those
standards, controls, and policies and procedures will totally shield the Group from liability, and
the Group remains exposed to the risk of potential civil and/or criminal actions leading to
damages, fines and sanctions...*

The risks of a liability in Canada on this very issue is flagged
up in the listing prospectus.

Right, so now we know.

So Haleon appear to have liability for OTC Zantac that
contains ranitidine as per the Canada.

I do not have information on how many other
countries OTC Zantac with that active ingredient
is available in.

Needs a statement from the company but can now
understand the fall and it was not an Elliott exit -
got this one wrong.

Elliott exit or stake reduction imho.

Added a small amount more before the close.

I'm back in & 2.85 and '87.

..

Unless I missed it.

As mentioned here a couple of times previously,
It can pay to be wary of uber bullish posters -
as we arguably saw here.